Trial Profile
A phase II study of GW572016 [lapatinib] and tamoxifen in patients with metastatic breast cancer resistant to single agent tamoxifen
Status:
Not stated
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2006
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Tamoxifen
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 08 Aug 2006 Status change
- 08 Aug 2006 New trial record.